Live Breaking News & Updates on Flexible Biologics
Stay updated with breaking news from Flexible biologics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shilpa Medicare rallied 10.46% to Rs 503 after the company said it has entered into a three-year definitive agreement with Dr. Reddy s Laboratories for production and supply of the Sputnik V vaccine.In an exchange filing on Monday, Shilpa Medicare said that through its wholly owned subsidiary, Shilpa Biologicals, will produce and supply the Sputnik V vaccine from its integrated biologics R&D cum manufacturing center at Dharwad, Karnataka. The targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses (50 million of Component 1 and 50 million of component 2), from the date of start of commercial production. Dr. Reddy s has partnered with HV/RDIF for clinical development of the vaccine and has distribution rights in geographies including India. Dr. Reddy s will facilitate the transfer of the sputnik technology to Shilpa Biologicals. Under the agreement, Shilpa Biologicals will be responsible for manufacture of the vaccine, while DRL is respo ....
For production of Sputnik V vaccineShilpa Medicare, via its wholly owned subsidiary, Shilpa Biologicals has entered into a 3 year definitive agreement with Dr Reddys Laboratories (DRL) for production-supply of Sputnik V vaccine from its integrated biologics R&D cum manufacturing center at Dharwad, Maharashtra. The targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses (50 million of Component 1 and 50 million of component 2), from the date of start of commercial production. DRL has partnered with HVIRDIF for clinical development of the vaccine and has distribution rights in geographies including India. DRL will facilitate the transfer of the sputnik technology to SBPL. Under the agreement, SBPL will be responsible for manufacture of the vaccine, while ....
Shilpa Medicare share jumps 14% on deal for production of Sputnik V vaccine The targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses (50 million of Component 1 and 50 million of component 2), from the date of start of commercial production BusinessToday.In | May 17, 2021 | Updated 17:55 IST Shilpa Medicare share rose 14 per cent to hit an intraday high of Rs 764.45 on BSE today after the company announced that its wholly owned subsidiary Shilpa Biologicals Private Limited (SBPL), has entered into a 3-year definitive agreement with Dr. Reddy s Laboratories Limited (DRL) for production-supply of the Sputnik V vaccine from its integrated biologics R&D cum manufacturing center at Dharwad, Karnataka. ....
Shilpa Medicare Limited ties up with Dr. Reddy'S Laboratories Limited for production of Sputnik V Vaccine equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.